TriSalus Life Sciences (TLSI) stock
Market cap $267M
Market closed. Prices as of Friday's close.
Members see every stock ranked and every check behind each score, live.
Why TLSI scores -3
PoorChoppy, 1 of 13 possible checks firingWhat the Quality Score means
Poor is below 0. Average starts at 6, Above Average at 11, Excellent at 15, and Exceptional at 20.
Well below its own recent run. TLSI scores -3 today, against a median of 2 over its last 20 recorded sessions.
- +3Growth sales up 25% on the year, gross margin up 1.1 pointsSales and margins against a year earlier: up to +3 for fast growth and widening margins, down to -2 when both shrink.
- −2Dilution 77.2% more shares outstanding than a year agoNew shares over the year: -1 at 10% more, -2 at 25% more.
- Momentum traits adds
- Long-term trend subtracts
- Size subtracts
- Profit subtractsRead on the last four quarters against the four before, or the last full year where no quarters are filed.
- Volatility subtractsA daily range of 5% or more with nothing behind it (no profit or cash flow, sales shrinking, or 10% more shares outstanding with no free cash flow): -1, or -2 from 8%.
- Cash flow subtracts-1 when free cash flow over the last four quarters is negative.
- News adds
No effect today: Run-up and Persistence.
Price, score, traits, and the industry rank are from a snapshot taken at 6:04 PM ET, at least 15 minutes behind. How we rank stocks.
What's next
Expected to report Thu Nov 12, after the close
After its last 4 reports it closed -7.2% on average, higher 2 of 4 times.
What would turn TLSI's score around: 8 things, for members
Here is what members see.
Every stock gets a card like this one, and a page with its price in real time, every line of its score, the chart, and its filings.
TLSI has 1 of a possible 13 checks firing
14 checks. Two are opposites (heavy volume and quiet volume), so at most 13 are on at once. One per group is shown here.
How TLSI ranks in Medical Devices
TLSI is #65 of 69 by Quality Score. The top three are shown with their scores, and the rest by name.
- 1
BLFSBioLife Solutions6/1318
- 2
HTFLHeartflow9/1317
- 3
WSTWest Pharmaceutical Services7/1317
DCTHDelcath SystemsOpen for its score
HAEHaemoneticsOpen for its score
- 65
TLSITriSalus Life Sciences1/13-3
When does TLSI report, and what happens after?
Expected to report Thu Nov 12, after the close (in 46 days). Not yet confirmed by the company.
| Reported | When | Gap | Reaction | 5 sessions |
|---|---|---|---|---|
| Aug 6, 2026After close | After close | +1.4% | +15.2% | +15.6% |
| May 12, 2026After close | After close | -21.1% | -41.5% | -30.9% |
| Mar 5, 2026After close | After close | -1.5% | -6.4% | -14.1% |
| Nov 13, 2025After close | After close | -6.8% | +3.9% | +13.0% |
The gap is the next open against the close before the report; the reaction is where that session closed. TLSI closed higher after 2 of its last 4. Past behavior, not a forecast.
Report dates and past reactions come from sessions that have already closed, so none of these figures move.
About TriSalus Life Sciences
TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.
Every line of the score, on every stock.
- Real-time prices, no delay
- Every line of TLSI's score, with the points and the reason
- All 14 checks on TLSI and on all 2,950 stocks
- Every stock ranked, with the chart
- Every filing, and optional alerts on TLSI
Straight answers.
Are the prices delayed?
Only on the public pages, which run at least 15 minutes behind. Members, trial included, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Where does the data come from?
Daily bars, quotes, reference data, headlines, and short interest come from Massive, formerly Polygon, a licensed market data vendor. The age of the quotes is shown at the top of every page. Insider trades, notable holders and profits come straight from the SEC. That means Form 4 filings, 13F filings and XBRL financial data on EDGAR. Government filings come from the public STOCK Act and Office of Government Ethics disclosures. The market-wide headlines on the market line also come from the public headline feeds CNBC, MarketWatch and Yahoo Finance publish, shown as the headline, the source and a link to the article. Splits, dividends, and the financial statements on each ticker page come from the vendor's reference data. The 8-K filings on EDGAR are read for the items that move a price. Five years of history is loaded for every stock. So the 200-day and 52-week traits rest on real history. Options flow is not part of the product.
What does it cost?
One plan with everything in it: $29 a month, $69 for three months, or $249 a year. You pick the billing period when the trial ends, and payments go through Stripe, so Breakaway never sees your card.
Is this investment advice?
No. It is a screening tool that scores stocks on the chart, the company's own results, and the news and filings. It does not know your situation and it is not a recommendation to buy or sell anything. Please do your own research.
The price, the score, the traits, and the industry rank on this page are delayed at least 15 minutes. Filings are shown as filed, because a disclosure is already days or weeks old when it becomes public. Earnings dates and past reactions are settled sessions.